Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
240 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05217407 | Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia(MASTERKEY ASIA) | recruiting | — | 1,000 | National Cancer Center, JapanOTHER_GOV | 7 | Mar 22, 2024 | clinicaltrials |
| NCT01120184 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | completed | Phase 3 | 1,095 | Hoffmann-La RocheINDUSTRY |
| 38 |
| Mar 4, 2024 |
| clinicaltrials |
| NCT05701735 | Decision Aid for Chemotherapy in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer(CECIL) | unknown | N/A | 45 | University of Santo Tomas Hospital, PhilippinesOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | terminated | Phase 2 | 63 | Debiopharm International SAINDUSTRY | 23 | Feb 7, 2024 | clinicaltrials |
| NCT03225586 | Prospective Urban Rural Epidemiology Study(PURE) | recruiting | — | 200,000 | Population Health Research InstituteOTHER | 25 | Jan 31, 2024 | clinicaltrials |
| NCT00957086 | Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer | unknown | Phase 3 | 710 | National Cancer Centre, SingaporeOTHER | 13 | Jan 9, 2024 | clinicaltrials |
| NCT00355238 | A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer | completed | Phase 2 | 137 | Bristol-Myers SquibbINDUSTRY | 8 | Dec 1, 2023 | clinicaltrials |
| NCT02941926 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC(COMPLEEMENT-1) | completed | Phase 3 | 3,246 | Novartis PharmaceuticalsINDUSTRY | 38 | Oct 24, 2023 | clinicaltrials |
| NCT01000025 | PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer | completed | Phase 3 | 720 | NCIC Clinical Trials GroupNETWORK | 12 | Aug 22, 2023 | clinicaltrials |
| NCT04742192 | Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer(EARLY-EGFR) | completed | — | 601 | AstraZenecaINDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT03185013 | REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)(REVEAL 1) | completed | Phase 3 | 201 | Inovio PharmaceuticalsINDUSTRY | 19 | Jul 27, 2023 | clinicaltrials |
| NCT02303444 | An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors(RIFTOS MKI) | completed | — | 667 | BayerINDUSTRY | 19 | Jun 8, 2023 | clinicaltrials |
| NCT00849667 | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse | terminated | Phase 3 | 1,100 | MorphotekINDUSTRY | 30 | Dec 30, 2022 | clinicaltrials |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | terminated | Phase 3 | 2,549 | AmgenINDUSTRY | 37 | Nov 30, 2022 | clinicaltrials |
| NCT05513248 | Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019 | completed | — | 16 | Lung Center of the PhilippinesOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT04109391 | Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 | completed | Phase 3 | 338 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Oct 26, 2022 | clinicaltrials |
| NCT01001377 | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | completed | Phase 3 | 1,010 | AmgenINDUSTRY | 29 | Sep 21, 2022 | clinicaltrials |
| NCT02162667 | Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer | completed | Phase 3 | 562 | CelltrionINDUSTRY | 22 | Aug 3, 2022 | clinicaltrials |
| NCT02898077 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | completed | Phase 3 | 440 | Eli Lilly and CompanyINDUSTRY | 4 | Jun 14, 2022 | clinicaltrials |
| NCT00920816 | Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer | completed | Phase 3 | 492 | PfizerINDUSTRY | 14 | May 6, 2022 | clinicaltrials |
| NCT04633564 | MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC | completed | Phase 3 | 671 | Mylan Pharmaceuticals IncINDUSTRY | 17 | Mar 16, 2022 | clinicaltrials |
| NCT02810457 | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer(AVANA) | completed | Phase 3 | 731 | Centus Biotherapeutics LimitedINDUSTRY | 24 | Mar 10, 2022 | clinicaltrials |
| NCT03556358 | Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | completed | Phase 3 | 809 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Jan 14, 2022 | clinicaltrials |
| NCT02213042 | Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 12 | Oct 13, 2021 | clinicaltrials |
| NCT02551159 | Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer(KESTREL) | completed | Phase 3 | 823 | AstraZenecaINDUSTRY | 23 | Oct 13, 2021 | clinicaltrials |
| NCT01077154 | Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | terminated | Phase 3 | 4,509 | AmgenINDUSTRY | 39 | Sep 28, 2021 | clinicaltrials |
| NCT01646437 | The International Polycap Study 3 (TIPS-3)(TIPS-3) | completed | Phase 3 | 7,793 | Population Health Research InstituteOTHER | 9 | Sep 16, 2021 | clinicaltrials |
| NCT03267641 | Prospective Cohort Study on the Clinical Trajectory of Resected Hepatocellular Carcinoma(PLANET) | completed | — | 86 | National Cancer Centre, SingaporeOTHER | 4 | Jun 9, 2021 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT03296163 | A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(STELLA) | completed | Phase 3 | 627 | mAbxience Research S.L.INDUSTRY | 18 | Apr 26, 2021 | clinicaltrials |
| NCT02367625 | Performance, Safety, and Efficacy of a New Cyrotherapy Device for Cervical Dysplasia | completed | N/A | 40 | JhpiegoOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02379845 | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall | completed | Phase 2 / Phase 3 | 180 | NanobiotixINDUSTRY | 13 | Apr 6, 2021 | clinicaltrials |
| NCT02485652 | Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung | terminated | Phase 2 | 162 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 10 | Jan 22, 2021 | clinicaltrials |
| NCT00381095 | A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer(COPE) | terminated | Phase 4 | 152 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc.INDUSTRY | 19 | Jan 20, 2021 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT01947608 | Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 10 | Nov 3, 2020 | clinicaltrials |
| NCT00080301 | Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | completed | Phase 3 | 752 | R-PharmINDUSTRY | 22 | Nov 2, 2020 | clinicaltrials |
| NCT00625898 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab(BETH) | terminated | Phase 3 | 3,509 | NSABP Foundation IncNETWORK | 40 | Sep 10, 2020 | clinicaltrials |
| NCT01984099 | RCT on the Efficacy of Methotrexate for the Prevention of GTD | completed | Phase 3 | 99 | University of the PhilippinesOTHER | 1 | Apr 17, 2020 | clinicaltrials |
| NCT02043288 | Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer | completed | Phase 3 | 310 | Orient Europharma Co., Ltd.INDUSTRY | 7 | Apr 15, 2020 | clinicaltrials |
| NCT02272413 | Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 671 | Boehringer IngelheimINDUSTRY | 28 | Jan 13, 2020 | clinicaltrials |
| NCT00294047 | Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older | completed | Phase 3 | 5,752 | GlaxoSmithKlineINDUSTRY | 12 | Jan 2, 2020 | clinicaltrials |
| NCT02066961 | A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer(ASPIRE-PCa) | completed | — | 1,533 | Astellas Pharma Global Development, Inc.INDUSTRY | 27 | Dec 20, 2019 | clinicaltrials |
| NCT00567190 | A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer(CLEOPATRA) | completed | Phase 3 | 808 | Genentech, Inc.INDUSTRY | 26 | Dec 13, 2019 | clinicaltrials |
| NCT00452569 | Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma(OPTIMUM) | completed | Phase 3 | 499 | CelgeneINDUSTRY | 15 | Nov 18, 2019 | clinicaltrials |
| NCT00937950 | Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects | completed | Phase 3 | 2,022 | GlaxoSmithKlineINDUSTRY | 13 | Oct 29, 2019 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials